Key Points
- CEO Eric Venker sold 200,000 Roivant Sciences shares at an average price of $35.77, generating $7.15 million and reducing his direct stake by 11.12% to 1.6 million shares.
- Roivant shares opened at $34.52 and have traded between $11.94 and $37.97 over the past year. The company beat quarterly EPS expectations but reported revenue below forecasts and remains unprofitable.
- Analysts maintain a generally positive outlook, with the stock carrying a consensus “Moderate Buy” rating and an average price target of $35.14; institutional investors own 64.76% of the company.
Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) CEO Eric Venker sold 200,000 shares of the company's stock in a transaction that occurred on Friday, August 28th. The shares were sold at an average price of $35.77, for a total value of $7,154,000.00. Following the transaction, the chief executive officer directly owned 1,599,154 shares in the company, valued at approximately $57,201,738.58. This represents a 11.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Eric Venker also recently made the following trade(s):
- On Monday, July 27th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $34.95, for a total value of $6,990,000.00.
- On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00.
Roivant Sciences Trading Down 0.3%
NASDAQ ROIV opened at $34.52 on Wednesday. The stock has a market cap of $24.93 billion, a PE ratio of -65.13 and a beta of 1.12. Roivant Sciences Ltd. has a 12 month low of $11.94 and a 12 month high of $37.97. The company's 50-day moving average price is $35.27 and its 200-day moving average price is $31.04.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04. The company had revenue of $1.44 million for the quarter, compared to analysts' expectations of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, sell-side analysts forecast that Roivant Sciences Ltd. will post -2 earnings per share for the current year.
Hedge Funds Weigh In On Roivant Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. VELA Investment Management LLC acquired a new position in shares of Roivant Sciences in the second quarter valued at about $207,000. Corient Private Wealth LP lifted its stake in Roivant Sciences by 48.7% during the 2nd quarter. Corient Private Wealth LP now owns 12,666 shares of the company's stock valued at $448,000 after acquiring an additional 4,148 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Roivant Sciences during the second quarter worth $2,166,000. California State Teachers Retirement System lifted its position in Roivant Sciences by 4,212.2% during the second quarter. California State Teachers Retirement System now owns 19,001,068 shares of the company's stock valued at $672,448,000 after purchasing an additional 18,560,434 shares during the period. Finally, HB Wealth Management LLC boosted its holdings in Roivant Sciences by 5.1% in the second quarter. HB Wealth Management LLC now owns 11,062 shares of the company's stock valued at $391,000 after purchasing an additional 537 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Analysts Set New Price Targets
A number of equities analysts recently commented on ROIV shares. Bank of America reissued a "neutral" rating on shares of Roivant Sciences in a research note on Friday, July 31st. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a research note on Thursday, August 6th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Guggenheim increased their price target on shares of Roivant Sciences from $36.00 to $42.00 and gave the company a "buy" rating in a research report on Friday, August 7th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Roivant Sciences in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $35.14.
View Our Latest Analysis on ROIV
About Roivant Sciences
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.
The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
